AND AIMS: Hearing loss (HL) is one of the most common sensory impairments worldwide and has substantial effects on quality of life and daily functioning. Although cochlear implants and hearing aids have markedly improved the management of hearing impairment, these devices do not directly address the underlying pathogenic mechanisms of HL....
✦ The floor
Discussion
Signed responses from readers of the wire.
No small-molecule therapy for hearing loss is currently approved for routine clinical use; this review is background science and requires no change to clinical practice at this time.
Small-molecule therapeutics represent a growing pipeline for hearing restoration, and this review consolidates current knowledge on cochlear targets, potentially informing future trial design and clinical translation timelines.
- 01Review surveys small-molecule drug candidates targeting cochlear mechanisms underlying hearing loss.
- 02Covers multiple therapeutic targets including hair cell regeneration, oxidative stress, and ion channel modulation.
- 03No small-molecule hearing-loss treatment is currently approved for routine clinical use.
- 04Quality-of-life impact of hearing loss is framed as a key motivator for drug development in this space.
- 05Findings are relevant to researchers tracking the hearing therapeutics pipeline.
Small-molecule therapies targeting cochlear mechanisms have potential to treat hearing loss and improve quality of life.
opinionpartially supportedCochlear mechanisms are viable pharmacological targets for hearing loss intervention.
studypartially supported- PMID
- 42859599
- DOI
- 10.1002/hsr2.73323.
- Journal
- Health Science Reports
- Publication type
- review
- Evidence level
- 5
- Population
- Not applicable — review of preclinical and clinical small-molecule hearing loss research
- Intervention
- Small-molecule therapeutic compounds targeting cochlear mechanisms
Primary outcomes
Cochlear mechanism targeting by small molecules; Impact on hearing loss outcomes; Quality of life implications